Suggestions
Stephan Grupp
Sickle cell gene therapy and CAR T cell expert. Director of Cancer Immunotherapy and Cell Therapy/Transplant Section at CHOP and Professor of Peds @ U Penn
Stephan Grupp is a prominent medical professional and researcher specializing in pediatric oncology, cell therapy, and immunotherapy. He currently holds several key positions at the Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania.
Professional Roles
Dr. Grupp serves as the Cellular Therapy and Transplant Section Chief at CHOP, a position he has held since May 2017.1 In this role, he oversees the integration of non-malignant Cell Therapy, Cancer Immunotherapy/CAR T, and Bone Marrow/Stem Cell Transplant into a single section within the Oncology department.1
Additionally, he holds the following positions:
- Medical Director of the cell and gene therapy lab at CHOP (since June 1999)1
- Director of Cancer Immunotherapy Frontier Program at CHOP (since July 2015)1
- Professor at the Perelman School of Medicine, University of Pennsylvania (since February 1996)1
Expertise and Research Focus
Dr. Grupp is recognized as an expert in:
- CAR T-cell therapy
- Sickle cell gene therapy
- Cancer immunotherapy
- Pediatric hematology/oncology
His work focuses on developing and implementing innovative cell therapies for treating pediatric cancers and other diseases.12
Education and Training
Dr. Grupp's educational background includes:
- MD/PhD from the University of Cincinnati College of Medicine (1981-1987)1
- Bachelor's Degree in Biology from the University of Cincinnati (1977-1981)1
He completed his pediatric residency at Boston Children's Hospital and a fellowship in Hematology/Oncology at Dana-Farber Cancer Institute.1
Achievements and Recognition
Dr. Grupp has received several honors for his contributions to the field, including:
- Membership in the National Academy of Medicine (2019)1
- Oski Prize and Lectureship from the American Society of Pediatric Hematology-Oncology (2015)1
- van Bekkum Prize from the European Bone Marrow Transplantation Society (2014)1
His work has significantly advanced the field of pediatric oncology and cell therapy, particularly in the development and application of CAR T-cell therapies for childhood cancers.3
